edoc

Items where Author is "Mamot, Christoph"

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Date | Item Type | Refereed
Jump to: Yes
Number of items: 4.

Yes

Pagani, Olivia and Klingbiel, Dirk and Ruhstaller, Thomas and Nole, Franco and Eppenberger-Castori, Serenella and Oehlschlegel, Christian and Bernhard, Jürg and Brauchli, Peter and Hess, Dagmar and Mamot, Christoph and Munzone, Elisabetta and Pestalozzi, Bernhard C. and Rabaglio, Manuela and Aebi, Stefan and Ribi, Karin and Rochlitz, Christoph and Rothgiesser, Karin and Thürlimann, Beat and von Moos, Roger and Zaman, Khalil and Goldhirsch, Aron and Swiss Group for Clinical Cancer, Research. (2017) Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99. Annals of Oncology, 28 (2). pp. 305-312.

Orleth, Annette and Mamot, Christoph and Rochlitz, Christoph and Ritschard, Reto and Alitalo, Kari and Christofori, Gerhard and Wicki, Andreas. (2016) Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy. Journal of Drug Targeting, 24 (1). pp. 80-89.

Wicki, Andreas and Wild, Damian and Prêtre, Vincent and Mansi, Rosalba and Orleth, Annette and Reubi, Jean-Claude and Rochlitz, Christoph and Mamot, Christoph and Mäcke, Helmut R. and Christofori, Gerhard. (2014) Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors. EJNMMI research, 4. p. 9.

Wicki, Andreas and Rochlitz, Christoph and Orleth, Annette and Ritschard, Reto and Albrecht, Imke and Herrmann, Richard and Christofori, Gerhard and Mamot, Christoph. (2012) Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth. Clinical cancer research, Vol. 18, no. 18. pp. 454-464.

This list was generated on Sun May 5 00:15:49 2024 CEST.